Callisto Pharmaceuticals Inc

Callisto Pharmaceuticals — Investor Presentation (October 2007)

24 slides from Callisto Pharmaceuticals's investor presentation, Oct 11, 2007

  1. Slide 1: Callisto Pharmaceuticals, Inc. (AMEX: KAL)

    Callisto Pharmaceuticals, Inc. (AMEX: KAL) Gary S. Jacob, Ph.D., CEO

  2. Slide 2: Forward-looking statements

    CALLISTO PHARMACEUTICALS, INC. Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected i

  3. Slide 3: Biotechnology Company Focused on Drugs to Treat Cancer & GI Conditions

    CALLISTO PHARMACEUTICALS, INC. Biotechnology Company Focused on Drugs to Treat Cancer & GI Conditions Atiprimod Phase II trial – advanced carcinoid cancer Phase I trial – multiple myeloma L-Annamycin Two Phase I trials in acute leukemia Guanilib Plan to enter Phase 1 trial - 1H 2008 Major new focus

  4. Slide 4: Callisto Pipeline

    DRUG & Phase INDICATION Preclinical I II lll ATIPRIMOD Carcinoid cancer Multiple myeloma L-ANNAMYCIN Adult relapsed ALL Pediatric relapsed ALL/AML GUANILIB (SP304) Chronic Constipation Irritable Bowel Syndrome Inflammatory Bowel Disease Callisto Pipeline

  5. Slide 5: Atiprimod – First-in-Class Azaspirane

    Novel drug candidate in clinical development for late-stage cancers Small-molecule, orally available Displays multiplicity of anti-cancer activities Promotes apoptosis, inhibitor of key signaling enzymes, anti-angiogenic activity Animal-model data show Atiprimod works in milieu of bone marrow Extens

  6. Slide 6: Atiprimod Clinical Development - Advanced Carcinoid Tumors

    Atiprimod Clinical Development - Advanced Carcinoid Tumors Potential benefit observed in carcinoid patients in Phase I trial of advanced cancer patients Phase II multi-center open-label clinical trial in advanced carcinoid cancer began November, 2006 Objective: evaluate efficacy in patients with met

  7. Slide 7: Atiprimod in Advanced Carcinoid Cancer - Market Overview

    Atiprimod in Advanced Carcinoid Cancer - Market Overview US prevalence: 80,000 – 100,000 8,000 new cases of per year in U.S.; 6% increase per annum Chemotherapy relieves symptoms in <30% of metastatic tumors Duration of response < 1 year Strong need for new effective therapy to treat advanced metast

  8. Slide 8: Atiprimod Competitive Landscape - Carcinoid cancer pipeline

    Atiprimod Competitive Landscape - Carcinoid cancer pipeline PHASE III Trial Octreotide +/- Evirolimus (Novartis). Study start: Dec. 2006 PHASE II Trials Panzem + Avastin (EntreMed). Study start: May 2006 Sunitinib following hepatic artery embolizations (Pfizer). Started Nov. 2006 Combo chemotherapy

  9. Slide 9: Atiprimod for Multiple Myeloma

    Atiprimod for Multiple Myeloma Phase I/IIa dose-escalation open-label study using amended protocol in relapsed or refractory multiple myeloma 25 subjects treated to date Atiprimod ascending dose plus ursodiol Maximum tolerated dose not yet reached Future clinical strategy under review Crowded landsc

  10. Slide 10: L-Annamycin

    L-Annamycin Second generation Anthracycline Unique patented liposomal formulation Potential to reduce cardiotoxicity and to treat multi-drug resistant tumors Proven class of anti-cancer drugs Active against multi-drug resistant tumors Strong myelosuppressive activity Potential to treat relapsed acut

  11. Slide 11: L-Annamycin Clinical Development

    L-Annamycin Clinical Development ADULTS Single-agent Phase I/IIa multi-center trial in adult relapsed or refractory ALL: Improvements in reconstitution and infusion protocol have led to de-escalation of drug dose Once MTD is established, plan to move to fixed-portion of trial – expected 4Q 2007 PEDI

  12. Slide 12: L-Annamycin - Market overview

    L-Annamycin - Market overview Target market – Adult Lymphocytic Leukemia Significant market opportunity with significant unmet medical need: U.S. incidence – 4,000 per year U.S. prevalence – 42,330 U.S. deaths – 1,400 per year Annual peak market in refractory ALL estimated to be $100 – $150 million

  13. Slide 13: Guanilib - New major strategic focus for Callisto

    Guanilib - New major strategic focus for Callisto Peptide hormone analogue to treat GI conditions Chronic constipation Constipation-predominant irritable bowel syndrome (IBS-C) Inflammatory bowel disease New class of drug Acts on receptor in gut lining Not systemically absorbed – low toxicity Only i

  14. Slide 14: Guanilib Unique peptide structure

    Guanilib Unique peptide structure 16-mer analog of uroguanilin Uroguanylin is a natural peptide produced in the lining of the gut Role in maintaining proper gut function Compact stable molecule Thermo and acid stable, resistant to proteases Behaves like a small molecule drug Not systemically absorbe

  15. Slide 15: Guanilib - Physiological mechanism

    Guanilib - Physiological mechanism Agonist of guanylate cyclase C (GC-C) receptor on luminal membrane of gut Agonists include guanylin (15-mer), uroguanylin (16-mer), bacterial enterotoxin – ST peptide (19-mer), linaclotide (14-mer) Activation elevates cGMP second messenger cGMP increases secretion

  16. Slide 16: Guanilib - Market overview

    Guanilib - Market overview The market potential for chronic constipation and IBS is huge In the US alone, about 26 million suffer from constipation - about 5 million of them severe 3 subtypes of IBS -- diarrhea-predominant (-D), mixed (-M) and constipation-predominant (-C) About 10 million people wi

  17. Slide 17: Guanilib - Competitive landscape (1)

    Guanilib - Competitive landscape (1) Chronic constipation and IBS-C Approved products Amitiza (lubiprostone) from Sucampo/Takeda Chloride C-2 channel activator – increases fluid secretion into small intestine Withdrawn products (in US) Zelnorm (tegaserod, 5-HT4 agonist), Novartis Withdrawn in US (20

  18. Slide 18: Guanilib - Competitive landscape (2)

    Guanilib - Competitive landscape (2) Chronic constipation & IBS-C pipeline Linaclotide from Microbia GC-C receptor agonist. Phase 2 TD-5108 from Theravance Inc. 5-HT4 receptor agonist. Phase 2 GSK abandoned partnership Sept 2007 Renzapride from Alizyme (UK) 5-HT4 agonist & 5-HT3 antagonist. Phase 2

  19. Slide 19: Guanilib - Competitive landscape (3)

    Guanilib - Competitive landscape (3) GC-C receptor agonist pipeline Only two compounds in this class Identical mechanisms of action Linaclotide from Microbia First in class Analog of E. coli ST peptide (cause of travelers diarrhea) In Phase 2b for chronic constipation and IBS-C Recently partnered wi

  20. Slide 20: Guanilib Proposed Initial Clinical Plan for GI Disorders

    Guanilib Proposed Initial Clinical Plan for GI Disorders File IND in early 2008 Phase I single-dose clinical trial in healthy volunteers Approx. 25 healthy volunteers Evaluate for safety, systemic absorption, pharmacodynamics Phase IIa 14-day, repeat-dose trial in chronic constipation patients Appro

  21. Slide 21: Callisto expected key developments - Next months

    Callisto expected key developments - Next 12 months 2Q2008 Initiate Guanilib Phase 1 trial 4Q2008 Commence Phase 1b repeat-dose trial for Guanilib in chronic constipation 1Q2008 Release interim data on Atiprimod Phase II carcinoid trial 1Q2008 FDA meeting to discuss pivotal trial for Atiprimod in ca

  22. Slide 22: Experienced Management Team

    Experienced Management Team Gary S. Jacob, Ph.D.; CEO, CSO 20 years experience in drug discovery & development G.D. Searle, Oxford University, and Monsanto Co. Robert C. Shepard, M.D., F.A.C.P.; Chief Medical Officer Senior Director, i3 Research Former Medical Officer, oncology branch of CBER at FDA

  23. Slide 23: Summary

    Summary Atiprimod for carcinoid cancer Progressing well Enrollment completed Interim data to be released in early 2008 L-Annamycin for leukemia Finalize MTD in adult and pediatric acute leukemia Development plan to be reviewed once data from adult trial is available Guanilib for chronic constipation

  24. Slide 24: Callisto Public Market Data

    Ticker / Exchange: KAL / AMEX Common Shares Outstanding (30 Sept. 2007): 45.5 million Series A Preferred Shares on “as converted” basis: 5.9 million Series B Preferred Shares on “as converted” basis: 22.9 million Total: 74.3 million Year End: December 31 Callisto Public Market Data

Callisto Pharmaceuticals — Investor Presentation (October 2007) on 6ix